title: Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
abstract: Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) account for approximately 30% of newly diagnosed cases of PC. The objective of BRPC therapy is to downstage the tumor to allow resection; the objective of LAPC therapy is to control disease and improve survival. There is no consensus on the definitions of BRPC and LAPC, which leads to major limitations in designing clinical trials and evaluating their results. A multimodality approach is always needed to ensure proper utilization and timing of chemotherapy, radiation, and surgery in the management of this disease. Combination chemotherapy regimens (5-fluorouracil, leucovorin, irinotecan, oxaliplatin, and gemcitabine [FOLFIRINOX] and gemcitabine/nab-paclitaxel) have improved overall survival in metastatic disease. The role of combination chemotherapy regimens in BRPC and LAPC is an area of active investigation. There is no consensus on the dose, modality, and role of radiation therapy in the treatment of BRPC and LAPC. This article reviews the literature and highlights the areas of controversy regarding management of BRPC and LAPC.
  
  
  CONCLUSIONS
  Pancreatic cancer is one of the worst cancers with regard to survival, even at early stages of the disease. This review evaluates all the evidence for the stages in which the cancer is not primarily resectable with surgery, known as borderline resectable or locally advanced unresectable. Recently, advancements in radiation techniques and use of better combination chemotherapies have improved survival and tolerance. There is no consensus on description of stages or treatment sequences (chemotherapy, chemoradiation, radiation), nor on the best chemotherapy regimen. The evidence behind the treatment paradigm for these stages of pancreatic cancer is summarized.
authors.affiliation: Department of Hematology and Oncology, Gastrointestinal Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA walid.shaib@emory.edu.
authors.forename: Walid L
authors.initials: WL
authors.lastname: Shaib
authors.affiliation: Department of Medicine, Emory University, Atlanta, Georgia, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Ip
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Cardona
authors.affiliation: Department of Hematology and Oncology, Gastrointestinal Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: Olatunji B
authors.initials: OB
authors.lastname: Alese
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: Shishir K
authors.initials: SK
authors.lastname: Maithel
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: David
authors.initials: D
authors.lastname: Kooby
authors.affiliation: Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: Jerome
authors.initials: J
authors.lastname: Landry
authors.affiliation: Department of Hematology and Oncology, Gastrointestinal Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
authors.forename: Bassel F
authors.initials: BF
authors.lastname: El-Rayes
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
keywords: Borderline resectable; Locally advanced unresectable; Pancreatic adenocarcinoma; Pancreatic cancer
references.citation: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):146-50
references.pmid: 12007953
references.citation: Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):739-47
references.pmid: 24882381
references.citation: J Clin Oncol. 2002 Jul 15;20(14):3130-6
references.pmid: 12118027
references.citation: Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):404-7
references.pmid: 12408777
references.citation: Oncology. 2003;64(3):191-206
references.pmid: 12697958
references.citation: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104
references.pmid: 12909221
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3296-302
references.pmid: 12947065
references.citation: J Clin Oncol. 2003 Sep 15;21(18):3409-14
references.pmid: 12972517
references.citation: Am J Clin Oncol. 2004 Feb;27(1):51-6
references.pmid: 14758134
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1430-8
references.pmid: 15084616
references.citation: Int J Gastrointest Cancer. 2003;34(2-3):107-16
references.pmid: 15361643
references.citation: J Clin Oncol. 2004 Sep 15;22(18):3776-83
references.pmid: 15365074
references.citation: Lancet. 1969 Oct 25;2(7626):865-7
references.pmid: 4186452
references.citation: Cancer. 1980 Oct 1;46(7):1518-22
references.pmid: 6998556
references.citation: Cancer. 1981 Oct 15;48(8):1705-10
references.pmid: 7284971
references.citation: J Can Assoc Radiol. 1981 Sep;32(3):164-5
references.pmid: 7028759
references.citation: J Clin Oncol. 1985 Mar;3(3):373-8
references.pmid: 3973648
references.citation: Cancer. 1985 Dec 1;56(11):2563-8
references.pmid: 2864997
references.citation: J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
references.pmid: 2898536
references.citation: J Clin Oncol. 1998 Jan;16(1):317-23
references.pmid: 9440759
references.citation: Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50
references.pmid: 16029791
references.citation: Radiother Oncol. 2005 Jul;76(1):48-53
references.pmid: 15990186
references.citation: Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3
references.pmid: 16168826
references.citation: Ann Surg Oncol. 2006 Feb;13(2):150-8
references.pmid: 16418882
references.citation: Ann Surg Oncol. 2006 Aug;13(8):1035-46
references.pmid: 16865597
references.citation: J Clin Oncol. 2007 Jan 20;25(3):326-31
references.pmid: 17235048
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2607-15
references.pmid: 17577041
references.citation: Medicina (Kaunas). 2007;43(9):716-25
references.pmid: 17986845
references.citation: J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8
references.pmid: 18471707
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3487-95
references.pmid: 18640929
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3496-502
references.pmid: 18640930
references.citation: Ann Oncol. 2008 Sep;19(9):1592-9
references.pmid: 18467316
references.citation: Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):678-86
references.pmid: 18395362
references.citation: Cancer. 2009 Feb 1;115(3):665-72
references.pmid: 19117351
references.citation: Ann Surg Oncol. 2009 Jul;16(7):1727-33
references.pmid: 19396496
references.citation: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):831-8
references.pmid: 19427747
references.citation: Jpn J Clin Oncol. 2010 Jun;40(6):573-9
references.pmid: 20185458
references.citation: Ann Surg Oncol. 2010 Aug;17(8):2092-101
references.pmid: 20224860
references.citation: Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42
references.pmid: 20171803
references.citation: Am J Clin Oncol. 2011 Feb;34(1):63-9
references.pmid: 20308870
references.citation: Surgery. 2011 Mar;149(3):311-20
references.pmid: 20817204
references.citation: Ann Surg Oncol. 2011 Mar;18(3):619-27
references.pmid: 21213060
references.citation: N Engl J Med. 2011 May 12;364(19):1817-25
references.pmid: 21561347
references.citation: J Clin Oncol. 2011 Aug 1;29(22):3037-43
references.pmid: 21709185
references.citation: Surgery. 2011 Sep;150(3):466-73
references.pmid: 21878232
references.citation: Am J Clin Oncol. 2011 Oct;34(5):460-5
references.pmid: 20881474
references.citation: J Clin Oncol. 2011 Nov 1;29(31):4105-12
references.pmid: 21969502
references.citation: Curr Drug Targets. 2012 Jun;13(6):781-8
references.pmid: 22458524
references.citation: BMC Cancer. 2012;12:199
references.pmid: 22642850
references.citation: Cancer. 2013 Jan 15;119(2):277-84
references.pmid: 22778019
references.citation: Oncologist. 2013;18(5):543-8
references.pmid: 23657686
references.citation: Am J Pathol. 2000 Sep;157(3):755-61
references.pmid: 10980115
references.citation: Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1275-9
references.pmid: 11286834
references.citation: Ann Surg Oncol. 2015 Apr;22(4):1153-9
references.pmid: 25358667
references.citation: Ann Surg Oncol. 2015 Oct;22(11):3512-21
references.pmid: 26065868
references.citation: Lancet Oncol. 2013 Apr;14(4):317-26
references.pmid: 23474363
references.citation: Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22
references.pmid: 23562768
references.citation: HPB (Oxford). 2013 Sep;15(9):661-7
references.pmid: 23458352
references.citation: J Surg Oncol. 2013 Sep;108(4):236-41
references.pmid: 23955427
references.citation: Pancreas. 2013 Nov;42(8):1311-5
references.pmid: 24152956
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: Oncologist. 2014 Mar;19(3):266-74
references.pmid: 24569947
references.citation: Br J Cancer. 2002 Jun 17;86(12):1864-70
references.pmid: 12085177